Takeda says cancer drug Alunbrig shows longer benefit vs. crizotinib

(This Nov. 23rd story corrects fiscal year of expected regulatory approval in the 10th paragraph to March-end 2021, not March-end 2020) By Rocky Swift (Reuters) – Japan’s biggest drugmaker, Takeda Pharmaceutical Co Ltd, said long-term data show better outcomes... More »